Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00080041 · ClinicalTrials.gov registry record · Phase 1
Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
A Phase 1 study, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00080041: Completed Phase 1 study, sponsored by Pharmacyclics.
NCT00080041 is a Phase 1 study that has completed, run by Pharmacyclics. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00080041, a Phase 1 study, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
Interventions
- DRUG Motexafin Gadolinium Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Phase | Phase 1 |
What the finished NCT00080041 record still lists
NCT00080041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 1 intervention - of which Motexafin Gadolinium Injection is the first listed.
NCT00080041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00080041 about?
NCT00080041 is a clinical study titled "Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors". The primary purpose of this study is to evaluate the safety, toxicities, and dosage for investigational drug Motexafin Gadolinium administered with docetaxel to patients with advanced solid tumors. Secondly, tumor response to the combined treatment will be evaluated.
What is the current status of trial NCT00080041?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants.
What interventions are being tested in trial NCT00080041?
The interventions under investigation include: Motexafin Gadolinium Injection (DRUG).
Who is sponsoring clinical trial NCT00080041?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00080041's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)